A group of prominent scientists, including Daniel Ebner from the TDI, shared their opinion in Nature Reviews Drug Discovery about ineffective academic and industrial drug discovery investments and funding structures. Parallel competitive research and development funding restricted to traditional drug discovery operating models is suggested as one major contributing factor to the exponential increase in the cost of new medicines.
International scientists call for a rethink on industrial and academic drug discovery
20 September 2016
A group of prominent scientists shared their opinion in Nature Reviews Drug Discovery about ineffective academic and industrial drug discovery investments and funding structures.